Avant Technologies JV with Austrianova Paves Way for Klotho-Based Therapies in Aging Biotech Sector
ByAinvest
Thursday, Sep 25, 2025 9:18 am ET1min read
Avant Technologies has formed a joint venture with Austrianova to develop cell-based therapies using encapsulated Klotho-producing cells for age-related conditions. The partnership leverages Austrianova's proprietary cell-encapsulation technology and intellectual property. Avant provides capital and operational resources to accelerate Klothonova's development pipeline, positioning the company to capitalize on the growing demand for precision healthcare solutions.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet